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One major obstacle for successful application of nanoparticles in medicine is its potential nanotoxicity on the
environment and human health. In this study, we evaluated the cytotoxicity effect of dimercaptosuccinic acid-coated
iron oxide (DMSA-Fe2O3) using cultured human aortic endothelial cells (HAECs). Our results showed that DMSA-Fe2O3
in the culture medium could be absorbed into HAECs, and dispersed in the cytoplasm. The cytotoxicity effect of
DMSA-Fe2O3 on HAECs was dose-dependent, and the concentrations no more than 0.02 mg/ml had little toxic effect
which were revealed by tetrazolium dye assay. Meanwhile, the cell injury biomarker, lactate dehydrogenase, was not
significantly higher than that from control cells (without DMSA-Fe2O3). However, the endocrine function for
endothelin-1 and prostacyclin I-2, as well as the urea transporter function, was altered even without obvious evidence
of cell injury in this context. We also showed by real-time PCR analysis that DMSA-Fe2O3 exposure resulted in
differential effects on the expressions of pro- and anti-apoptosis genes of HAECs. Meanwhile, it was noted that
DMSA-Fe2O3 exposure could activate the expression of genes related to oxidative stress and adhesion molecules,
which suggested that inflammatory response might be evoked. Moreover, we demonstrated by in vitro endothelial
tube formation that even a small amount of DMSA-Fe2O3 (0.01 and 0.02 mg/ml) could inhibit angiogenesis by the
HAECs. Altogether, these results indicate that DMSA-Fe2O3 have some cytotoxicity that may cause side effects on
normal endothelial cells.
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The application of magnetic nanoparticles (MNPs) in
diagnosis and effective treatment of diseases has be-
come an area of increasing interest in the biomedical
sciences [1-4]. Drug delivery is used to carry drugs
region-specifically by attaching them to MNPs and re-
leasing the drug in vivo to the target locale [5-9]. Via
AC magnetic fields, the MNPs can mediate hyperther-
mia for in situ cancer-targeted therapy and be used for
in vitro cancer cell-targeted detecting systems [10-14].* Correspondence: chenxiangjian@njmu.edu.cn; diyang@njmu.edu.cn
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in any medium, provided the original work is pSimilarly, cells of interest labeling with large amounts of
MNPs can be located, tracked, and recovered by im-
aging techniques such as high-resolution magnetic res-
onance imaging [15-18].
MNPs of iron oxide (Fe3O4, γ-Fe2O3) may develop to
be the modest and biocompatible one with the rapid
progress in biological applications research [19,20].
Many investigations have studied the use of diverse or-
ganic coatings as a way of optimizing the delivery of
MNPs to or into cell. Several studies have confirmed
that a simple dimercaptosuccinic acid (DMSA) coating
can enhance the rate of uptake by three orders of mag-
nitude, presumptively by engendering the MNPs with
an anionic charge, leading to nonspecific adsorption to
the cell surface followed by endocytosis into the cell
[21-23]. These methods can deliver huge amounts of
MNPs into the cells, but a proven concern arises overpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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MNPs might have on normal cell behavior. A quantita-
tive model cell system indicates that intracellular deliv-
ery of even restrained levels of iron oxide (Fe2O3)
nanoparticles may affect cell function. To be more spe-
cific, the cytotoxicity investigations show that exposure
to mounting concentrations of anionic MNPs, from
0.15 to 15 mM of iron, results in a dose-dependent de-
creasing viability and capacity of PC12 cells to spread
neurites in return for nerve growth factor [24].
In addition to drug delivery, many biomedical applica-
tions of MNPs such as magnetic tracking and hyperther-
mia need a very great deal of MNPs to be injected into
blood vessels, which are lined by endothelial cells (ECs),
a single squamous epithelial cell layer and an anticoa-
gulant barrier between the vessel wall and blood. EC is
involved in the immune and inflammatory response, co-
agulation, growth regulation, production of extracellular
matrix components, and is a modulator of blood flow
and blood vessel tone. EC injury, activation, or dysfunc-
tion is a hallmark of many pathologic states including
atherosclerosis, loss of semi-permeable membrane func-
tion, and thrombosis [25]. A wide variety of stimuli can
induce programmed cell death (apoptosis) of endothelial
cells through extrinsic (death receptor) and/or intrinsic
(mitochondria) apoptotic pathway, which is ultimately ex-
ecuted by the intracellular proteases called caspases. There
also exist caspase-independent pathways of apoptosis and
anti-apoptotic proteins, which can protect cells from
apoptosis. These pathways and proteins compose the
complicated network of the cell apoptosis [26-29]. When
injecting MNPs into blood vessels, ECs is the first tissue
barrier encountered by the MNPs. The focus of this study
is thus on the cytotoxicity evaluation of DMSA-coated
Fe2O3 nanoparticles (DMSA-Fe2O3) on human aortic
endothelial cell (HAEC), which is able to proliferate for
many generations maintaining its endothelial characteris-
tic and is widely used for in vitro study [30].
Methods
Materials
Dulbecco's modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were purchased from GIBCO
Company (Grand Island, New York, USA). Endothelial
cell growth supplement (ECGS) was supplied by M&C
Gene Technology (Beijing, China). MEM non-essential
amino acid solution (100×), L-glutamine, thiazolyl blue
tetrazolium bromide, haematoxylin, penicillin, and strep-
tomycin were obtained from Sigma-Aldrich (St Louis,
MO, USA). Prostacyclin I-2 (PGI-2), endothelin-1 (ET-1),
and nitric oxide (NO) assay kits were obtained from
Nanjing Jiancheng Bioengineering Institute (Nanjing,
China). Primers were synthesized by Sangon Biotechnology
Co., Ltd. (Shanghai, China), and RNAiso Plus reagent,PrimeScript™ RT reagent Kit, and SYBR Premix Ex Taq™
were from TaKaRa Biotechnology Co., Ltd. (Dalian, China).
Matrigel basement membrane matrix was from Becton
Dickinson (Bedford, MA, USA).Preparation of DMSA-Fe2O3 nanoparticles
The DMSA-Fe2O3 was prepared by co-authors Dr. Fei
Xiong, Dr. Yu Zhang, and Dr. Ning Gu. The charac-
terization data, such as transmission electronic micros-
copy (TEM) images, crystal structure, surface charge,
and magnetic measurements and Fourier transform in-
frared spectroscopy measurements were determined as
the previous report in Dr. Gu's Lab [31]. In the present
study, quasi-spherical DMSA-Fe2O3 with an average
diameter of 10 nm, was diluted in deionized water to 1
mg/ml, and then further diluted in tested concentra-
tions with cell culture medium before using.Cell culture
HAECs were used for experiments at passages 2 to 5.
HAECs were cultured in DMEM supplemented with
1% ECGS, 20% FBS, 1% heparin sodium, 1% non-
essential amino acid solution (100×), 1% L-glutamine,
100 U/ml penicillin, and 100 U/ml streptomycin. Cells
were maintained at 37°C in a humidified incubator with
5% CO2.Location of DMSA-Fe2O3 in the HAEC
For TEM analysis, the HAECs incubated with 0.02 mg/ml
DMSA-Fe2O3 for 24 h were washed with PBS and rou-
tinely fixed, dehydrated, and embedded [32]. Ultrathin
sections (80 nm) were transferred to the 200 mesh copper
grid, stained with 5% lead tetraacetate, air-dried, and then
examined with a TEM (JEM-1010, JEOL, Akishima-shi,
Japan) at 80 kV.Cell viability/cytotoxicity assay
The cytotoxicity of DMSA-Fe2O3 against HAECs was
investigated by the tetrazolium dye (MTT) assay [33].
For the dose-dependent effect, the DMSA-Fe2O3, diluted
with culture medium at graded concentrations from
0.001 to 0.2 mg/ml, was applied to the HAECs for 24 h.
For the time-dependent effect, 0.05 mg/ml of DMSA-
Fe2O3 was applied to the cells for 4, 24, 48, and 72 h,
respectively. After washing with PBS, the cells were
incubated with MTT solution at 37°C for 2 h, and the
dyes were dissolved by dimethyl sulfoxide (DMSO) for
15 min. Absorbance was examined at 595 nm with the
Ultra Microplate Reader ELX808IU, and cell viability
was calculated as a percentage of control cells treated
without DMSA-Fe2O3. Each experiment was repeated at
least three times independently.
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factors
In this study, HAECs were co-cultured with 0.02 mg/ml
of DMSA-Fe2O3 for 24 h. Then, the cell culture super-
natant was centrifuged at 8000 × g, 4°C for 30 min to re-
move the rest of the nanoparticles and cell debris. ET-1,
PGI-2, and NO concentrations in the supernatant were
measured using ELISA kits according to the manu-
facturer's instructions, respectively. Lactate dehydro-
genase (LDH) and urea were determined using an
automatic biochemistry analyzer (Olympus AU5400,
Olympus Corporation, Shinjuku-ku, Japan).
Real-time PCR analysis of HAEC gene expression
Thirty-eight genes related to apoptosis cascade, endo-
plasmic reticulum (ER) stress, oxidative stress, adhesion
molecules, and calcium-handling proteins were detected
by real-time PCR. In this study, HAECs were incubated
with 0.02 mg/ml of DMSA-Fe2O3 for 24 h. The total
RNA (300 ng) extracted from HAECs was reverse-
transcribed using the PrimeScript™ RT reagent Kit, and
then the cDNA was amplified using the SYBR Premix
Ex Taq™ according to the following cycle conditions: 30 s
at 95°C for 1 cycle, 5 s at 95°C, and 30 s at 60°C for 40
cycles (AB 7900HT Fast Real-Time PCR system). All
real-time PCR reactions were performed in triplicate.
The housekeeping gene GAPDH was used as an internal
control. The fold changes of target gene expression rela-
tive to those of the control group were analyzed by the
2−ΔΔCT method [34], divided into different ranges and
depicted as different colors.
Effects of DMSA-Fe2O3 on HAEC tube formation
The tube formation assay is one of the most widely used
assays to model the reorganization stage of angiogenesis
in vitro. The assay measures the ability of endothelial
cells, plated at subconfluent densities with the appropri-
ate extracellular matrix support, to form capillary-like
structures. In this study, the Matrigel basement mem-
brane matrix was used as extracellular matrix support to
observe whether angiogenesis of HAEC can be inter-
vened by DMSA-Fe2O3 or not. For HAEC tube forma-
tion, 50 μl/well of the Matrigel basement membrane
matrix was added to a 96-well plate and allowed to gel
for 60 min at 37°C. Then, HAECs were seeded at a dens-
ity of 1.5 × 104 cells/well on the surface of the gel in the
presence or absence of conditioned DMSA-Fe2O3 and
incubated for 14 h at 37°C in a CO2 incubator. Mean-
while, the high urea solution (6M urea) was used as a
positive control for inhibition of tube formation. The
cultures on the gel were fixed for 10 min in 25% glutar-
aldehyde, washed, and stained with Mayer’s hematoxylin.
Each well was inspected under a light microscope at ×100
magnification and captured more than three pictures fromdifferent fields. Image-Pro plus (IPP) 6.0 for Windows
software (Media Cybernetics, Inc., Rockville, MD, USA)
was used to measure the length of tube formation on each
picture. The average data from the same well was calcu-
lated as its quantitative value.
Statistical analysis
The data were represented as mean ± SD of no less than
three independent experiments. Statistical analysis was
performed using a student's t test. A value of p < 0.05
was considered statistically significant.
Results and discussion
Endocytosis of DMSA-Fe2O3 by HAECs
We were able to recognize the DMSA-Fe2O3 inside the
HAECs and distinguish them from the cellular struc-
tures by their high electron density on TEM. Figure 1
represents TEM micrographic images between HAECs
incubation with 0.02 mg/ml of DMSA-Fe2O3 (Figure 1c,d)
and HAECs without DMSA-Fe2O3 incubation (Figure 1a,b).
The results indicate that the DMSA-Fe2O3 aggregates
are readily absorbed by the cells without disrupting
the integrity of the cellular membrane and dispersed
in the cytoplasm.
HAECs viability studies
The tetrazolium dye (MTT) assay has been used for
detecting the number of viable cells (proliferation) and
loss of viable cells (cytotoxicity) resulting from toxic ma-
terials since only living cells can reduce the MTT to its
insoluble form, formazan, which can be quantitatively
measured after dissolved in DMSO by a spectrophotom-
eter, and the resultant value is linked to the number of
living cells [35].
In the present study, the viability of HAECs was ap-
parently decreased with increased DMSA-Fe2O3 concen-
trations compared with that of control cells (Figure 2a).
HAECs treated with the concentrations under 0.05 mg/ml
of DMSA-Fe2O3 for 24 h did not induce any cell losses. In
contrast, DMSA-Fe2O3 at the high doses (greater than
0.05 mg/ml) resulted in significant cell loss thereby
cytotoxic. The cell viability of HAECs incubated with
DMSA-Fe2O3 at the concentration of 0.2 mg/ml was ap-
proximately decreased to 56.7% of the control cells.
To study the time-dependent effect of DMSA-Fe2O3
on HAECs viability, cells were incubated with 0.05 mg/ml
of DMSA-Fe2O3 for 4, 24, 48, and 72 h, respectively
(Figure 2b). Decreased cell viability occurred as early as
4 h and varied in a range from 75.8% to 93.1% to the
control group at tested time points. The results suggest
that the cytotoxic effect of DMSA-Fe2O3 on HAECs is
dose-dependent, and the concentrations no more than
0.02 mg/ml are relatively harmless in the present study.
Figure 1 The TEM images of HAECs incubated with 0.02 mg/ml of DMSA-Fe2O3 for 24 h. (a) HAEC without DMSA-Fe2O3 (×8,000). (b) HAEC
without DMSA-Fe2O3 (×30,000). (c) HAEC incubated with DMSA-Fe2O3 (×5,000). (d) HAEC incubated with DMSA-Fe2O3 (×30,000). Abbreviations:
n, nucleus; v, vesicle; Arrows denote the DMSA-Fe2O3 or particulate matter.
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LDH is a cytoplasmic enzyme which can be released to the
extracellular space because of the disturbances of the cellu-
lar integrity induced by pathological conditions. Therefore,
supernatant LDH of cultured HAECs is detected as a
marker for cell injury [36]. We found that there was no dif-
ference in LDH released from the HAECs incubated with
0.02 mg/ml DMSA-Fe2O3 for 24 h and the control cells
(Figure 3). This finding was consistent with the results of
little cytotoxicity effect in MTT assay (Figure 2a) and cell
membrane integrity changes shown by TEM (Figure 1c,d).
We then examined whether the endocrine function of
HAECs was changed when exposed to this low dose of
DMSA-Fe2O3 that did not cause measurable cell injury.
ECs can regulate blood pressure and blood flow by re-
leasing vasodilators such as NO and PGI-2, as well as
vasoconstrictors, including ET-1. So, the endocrine func-
tion of cultured HAECs can be assessed by detecting the
above-mentioned factors in the supernatant. We found
that the release of NO was not changed in the HAECs
treated with 0.02 mg/ml DMSA-Fe2O3 for 24 h (Figure 3).
NO released toward the vascular lumen is the most
important stimulator for vascular dilator and a potentinhibitor of platelet aggregation and adhesion. NO
protects against the onset and later steps in athero-
genesis, and thus is one of the most important pro-
tective molecules in the vasculature. Endothelial NO
synthase (eNOS) is the predominant NOS isoform in
the vasculature responsible for most of the vascular
NO production. A functional eNOS oxidizes its sub-
strate L-arginine to L-citrulline and NO. Our results
indicate that the eNOS function in the HAECs is not
affected by treatment with 0.02 mg/ml DMSA-Fe2O3
for 24 h.
In contrast to the release of NO, the release of an-
other vasodilator PGI-2 and the vasoconstrictor ET-1
was significantly decreased in the HAECs treated with
0.02 mg/ml DMSA-Fe2O3 for 24 h (Figure 3, p < 0.01
vs. control group). Besides its function as an effective
vasodilator, PGI-2 can prevent platelet plug formation
by inhibiting platelet activation. PGI-2 is produced in
endothelial cells from prostaglandin H2 by the action of
the enzyme PGI-2 synthase. ET-1 is secreted constitu-
tively by endothelial cells from its inactive intermediate,
big ET-1, through the action of endothelin-converting
enzyme, which is present at the EC surface and on
intracellular vesicles. Expression and release of PGI-2
Figure 2 The viability of HAECs incubated with DMSA-Fe2O3. Data are expressed as mean ± SD from independent experiments. Control
values from HAECs incubated without DMSA-Fe2O3 were defined as 1. (a) HAECs were incubated with DMEM containing the gradient
concentrations of DMSA-Fe2O3 for 24 h (0.001, 0.01, 0.02, 0.05, 0.1, 0.2 mg/ml), n = 7. (b) HAECs were incubated with DMEM containing
0.05 mg/ml DMSA-Fe2O3 for the indicated time (4, 24, 48, 72 h). n = 5. *p < 0.05 vs. control; **p < 0.01 vs. control.
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we did not study the mechanism for their reducing ex-
pressions and/or release in this study. However, our re-
sults demonstrate that the endocrine functions of
HAECs are sensitive to DMSA-Fe2O3 treatment, and
these functions may be interfered before severe cell in-
juries occur.
In addition to the cellular-releasing function of these
vessel tone regulators, we also studied the cellularuptake function by examining the urea transporter
function. The transporter for urea is expressed in the
vascular endothelium that transports urea into the cell.
Urea plays a significant role in the endothelial cell, and
previous studies have revealed that uremic levels of
urea (25 mM) inhibit L-arginine transport in cultured
endothelial cells [37]. In this study, we found that the
urea concentration in the HAECs treated with 0.02
mg/ml of DMSA-Fe2O3 for 24 h was significantly
Figure 3 Levels of injury marker, LDH, and endocrine factors in supernatant of HAECs. Incubated with 0.02 mg/ml DMSA-Fe2O3 for 24 h.
Ratios relative to the control cells (without DMSA-Fe2O3) are shown. *p < 0.05 vs. control; **p < 0.01 vs. control.
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This observation suggests that the function of urea
transporter in the HAECs is also inhibited by the
DMSA-Fe2O3 exposure.
Gene expression on HAECs
Endothelial cell death, which can be caused by environ-
mental stresses such as oxidative stress, endoplasmic
reticulum stress, and adhesion molecules, is mostly
apoptotic [26]. We thereby examined gene expression
related to the apoptosis cascade, endoplasmic reticulum
stress, oxidative stress, adhesion molecules, and calcium-
handling proteins (Figure 4). After the HAECs were
incubated with 0.02 mg/ml of DMSA-Fe2O3 for 24 h,
the expressions of most of genes involved in the apoptosis
cascade and calcium-handling proteins were changed
from 0.5- to 1.5-fold compared to those of HAECs with-
out DMSA-Fe2O3 treatment, except MAPK14 (mitogen-
activated protein kinase 14, MAPK14, also called p38-α),
CASP3 (caspase 3), and BCL2 (Bcl-2). Caspase 3 [38] and
Bcl-2 [27], which promote cell death and inhibit cell death,
respectively, were increased by over 1.5-fold in mRNA
expression in the experiment group. In contrast, the ex-
pression of proapoptotic MAPK14 [39] in DMSA-Fe2O3-
treated HAECs was decreased to less than 0.5-fold to that
of the control cells. Therefore, the DMSA-Fe2O3 caused
differential effects on the expression of pro- and anti-
apoptosis genes of HAECs; this may explain why the via-
bility of HAECs was not changed at this low concentration
of DMSA-Fe2O3, which might not be sufficient to activate
the cell apoptosis pathway.In this study, the expressions of all four tested genes
involved in ER stress, were down-regulated in DMSA-
Fe2O3-treated HAECs (Figure 4), especially the AFT4
gene (activating transcription factor 4), whose expres-
sion was decreased by over 50%. In contrast, most of
the examined genes related to oxidative stress showed
an increased change in DMSA-Fe2O3-treated HAECs
with the expression of SOD2 (superoxide dismutase 2)
and PTGS2 (cyclooxygenase-2, COX-2) elevated to 1.96-
and 2.44-fold, respectively. COX-2 is unexpressed under
the normal conditions but elevated during an inflamma-
tion. The data suggest that oxidative stress, not ER stress,
is sensitive to DMSA-Fe2O3. In addition, the expression of
NOS3 (eNOS) was mildly decreased in DMSA-Fe2O3-
treated HAECs, which was consistent to the result of NO
concentration (Figure 3).
We found up-regulation of gene expression for cell-
cell contact and adhesion including ICAM1 (intercellular
adhesion molecule 1, ICAM-1), VCAM1 (vascular cell
adhesion protein 1, VCAM-1), and SELE (endothelial-
leukocyte adhesion molecule 1, E-selectin) (3.3-, 4.9-,
and 8.1-fold, respectively, Figure 4). ICAM-1 is a type of
intercellular adhesion molecule which continuously pre-
sents in low concentrations in the membranes of leuko-
cytes and endothelial cells, and greatly increases upon
cytokine stimulation. VCAM-1 and E-selectin are cell
adhesion molecules expressed only after the endothelial
cells being stimulated by cytokines and thus play an
important role in inflammation. Thus, together with
the data from genes associated with oxidative stress,
the results of adhesion molecular genes indicate that
Figure 4 Fold changes in gene expression: apoptosis, adhesion molecules, ER stress, oxidative stress, and calcium-handling proteins.
The changes of HAECs incubated with 0.02 mg/ml DMSA-Fe2O3 for 24 h to control the cells (HAECs without DMSA-Fe2O3) were analyzed by
the 2−ΔΔCT method. Gene symbols and corresponding encoded proteins: MAP3K5, apoptosis signal-regulating kinase 1 (ASK1); TRAF2, tumor
necrosis factor receptor-associated factor 2 (TRAF2); DAB2IP, ASK1-interacting protein (AIP1); MAPK8, mitogen-activated protein kinase 8 (JNK1);
MAPK9, mitogen-activated protein kinase 9 (JNK2); MAPK14, mitogen-activated protein kinase 14 (p38 MAPK α); ERN1, endoplasmic reticulum to
nucleus signaling 1 (IRE1); BCL2, B-cell lymphoma 2 (Bcl-2); BAX, Bcl-2-associated X protein (Bax); NKRF, nuclear factor-κB repressing factor; TXN,
thioredoxin; CTSB, cathespin B; CYCS, cytochrome C; CASP9, caspase-9; CASP3, caspase-3; EIF2AK3, eukaryotic translation initiation factor 2α kinase 3
(PERK); ATF4, activating transcription factor 4; DDIT3, DNA-damage-inducible transcript 3 (CHOP); EIF2A, eukaryotic translation initiation factor 2α;
NOS3, nitric oxide synthase 3 (eNOS); SOD1, super oxide dismutase 1 (SOD-1); SOD2, super oxide dismutase 2 (SOD-2); ROMO1, reactive oxygen
species modulator 1; PTGS1, cyclooxygenase 1 (COX-1); PTGS2, cyclooxygenase 2 (COX-2); VCAM1, vascular cell adhesion molecule 1 (VCAM-1);
ICAM1, intercellular adhesion molecule 1(ICAM-1); ICAM2, intercellular adhesion molecule 2 (ICAM-2); SELE, endothelial-leukocyte adhesion
molecule 1 (E-selectin); PLCG1, phospholipase C γ1; PLCG2, phospholipase C γ2; ITPR1, inositol 1,4,5-trisphosphate receptor type 1; ITPR2, inositol
1,4,5-trisphosphate receptor type 2; ITPR3, inositol 1,4,5-trisphosphate receptor type 3; CALM1, calmodulin 1.
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lowing 0.02 mg/ml DMSA-Fe2O3 treatment before the
onset of cell death.
Effects of DMSA-Fe2O3 on HAECs tube formation
Angiogenesis, the formation of new capillaries from
preexisting blood vessels, is a motile process involving
ECs activation. The migration of ECs is essential to
angiogenesis and this complex process may be induced
by kinds of mediators including cytokines, growth
factors, and cell adhesion molecules. In physiological
conditions, angiogenesis occurs in development and
wound healing. However, pathological angiogenesis
plays an essential role in cancer cell growth. The in-
hibition or antagonism of angiogenesis has been the
focus of extensive basic and clinical research [40,41].
To further determine the effect of DMSA-Fe2O3 on
angiogenesis by the HAECs, we performed endothelialtube formation assay using the Matrigel basement mem-
brane matrix. We found that while HAECs without
DMSA-Fe2O3 treatment formed a capillary-like network
on Matrigel-coated wells within 14 h (Figure 5a), on the
opposite, HAECs treated with 6M urea failed to form
tubes due to its high osmolality (Figure 5d). Importantly,
an obvious failure to form networks by the HAECs in the
presence of DMSA-Fe2O3 with 0.01 (Figure 5b) and 0.02
mg/ml (Figure 5c) concentrations was observed. The
length of the formed tube was decreased to 42.5% and
19.1% of the normal control at 0.01 and 0.02 mg/ml
DMSA-Fe2O3, respectively (Figure 6). The elevated ex-
pressions of cell adhesion molecules might be responsible
for the failed tube formation. The angiogenesis assay sug-
gests that even a small amount of DMSA-Fe2O3 is also
harmful to the angiogenesis of normal endothelial cells,
which is an essential process in embryo development and
wound healing.
Figure 5 Effect of DMSA-Fe2O3 on tube network formed by HAECs cultured on Matrigel within 14 h. (a) HAECs can form a capillary-like
network on Matrigel-coated wells within 14 h. (b) An obvious failure to form networks by HAECs in the presence of 0.01 mg/ml DMSA-Fe2O3.
(c) Few tube networks by HAECs in the presence of 0.02 mg/ml DMSA-Fe2O3. (d) The high urea solution (6M urea) was used as a positive control
for the inhibition of tube formation.
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In summary, the present study shows that DMSA-Fe2O3
nanoparticles absorbed by the HAECs can cause a dose-
dependent cytotoxic event. HAECs exposed to even a small
amount of DMSA-Fe2O3 may have impaired endocrineFigure 6 Length of tube networks formed by HAEC cultured on Matri
the length of tube networks (pixels). The stained cells were inspected und
than three pictures from different fields. The average data from the same
mean ± SD. **p < 0.01 vs. control.function and angiogenic functions without obvious cell tox-
icity. Furthermore, the genes related to oxidative stress and
inflammation response were activated. Therefore, cautious
evaluation of DMSA-Fe2O3 nanoparticles in vivo is needed
before applying them in medicine.gel. Image-Pro plus 6.0 for Windows software was used to measure
er a light microscope at ×100 magnification and captured more
well was calculated as its quantitative value. Data are expressed as
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